Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pharmacology, Clinical
Conditions
Pharmacology, Clinical
Trial Timeline
Mar 1, 2009 → Jul 1, 2010
NCT ID
NCT00855660About Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg + Placebo
Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg + Placebo is a phase 1 stage product being developed by Bayer for Pharmacology, Clinical. The current trial status is completed. This product is registered under clinical trial identifier NCT00855660. Target conditions include Pharmacology, Clinical.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00855660 | Phase 1 | Completed |
Competing Products
16 competing products in Pharmacology, Clinical